BC Extra | Feb 22, 2018
Preclinical News

New fluorination method expands medicinal chemistry toolbox

In a paper published in Nature , a group from the Max Planck Institute and Harvard University describe a method to fluorinate a wider array of aromatic carbon-hydrogen bonds than currently available methods allow. The method...
BC Innovations | Jun 5, 2014

Sanford-Burnham goes fourth

Sanford-Burnham Medical Research Institute 's outreach to industry has resulted historically in deals focused either on a narrow range of projects or the work of individual investigators, but the institute also has been seeking broader...
BC Week In Review | May 6, 2013
Company News

Novartis pharmaceuticals news

The U.S. Attorney's Office for the Southern District of New York filed on April 26 a civil suit against Novartis' Novartis Pharmaceuticals Corp. subsidiary seeking damages and penalties under the False Claims Act and under...
BC Week In Review | Nov 12, 2012
Company News

Ajinomoto, Astellas deal

In its earnings for fiscal 2Q12 ended Sept. 30, Astellas said the companies partnered in October to conduct trials of Starsis nateglinide in combination with inhibitors of dipeptidyl peptidase-4 (DPP-4) . The companies could not be...
BC Innovations | Sep 13, 2012
Distillery Therapeutics

Indication: Endocrine/metabolic disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Endocrine/metabolic disease Diabetes Unknown Rat studies suggest antidiabetic prodrugs engineered to release nitric oxide (NO) could reduce cardiovascular risks associated with treatment. In nonfasted diabetic rats,...
BC Week In Review | Sep 19, 2011
Clinical News

Glucagon-like peptide-1 endocrine/metabolic data

Researchers at the university reported data showing that the use of GLP-1-related therapies Januvia sitagliptin and Byetta exenatide showing was associated with a significant sixfold increased rate of reported pancreatitis vs. 4 other marketed Type...
BC Week In Review | Mar 22, 2010
Clinical News

Diovan valsartan: Phase III data

Novartis reported data from the prospective, double-blind, placebo-controlled, international Phase III NAVIGATOR trial in 9,306 patients with impaired glucose tolerance and cardiovascular disease or risk factors receiving either once-daily Diovan or thrice-daily Starlix nateglinide. Diovan...
BC Extra | Mar 16, 2010
Clinical News

Novartis reports NAVIGATOR data

Novartis AG (NYSE:NVS; SIX:NOVN) reported data from the Phase III NAVIGATOR trial of once-daily Diovan valsartan and thrice-daily Starlix nateglinide to delay progression to Type II diabetes in patients with impaired glucose tolerance and cardiovascular...
BC Innovations | May 8, 2008
Cover Story

A gut feeling

Many treatments for metabolic disorders such as obesity and type 2 diabetes directly target the brain or liver ( see "Controlling the liver via the gut" and "Targeting diabetes and obesity" ). 1 Although neural communication...
BioCentury | Mar 10, 2008

Time & numbers

Time & numbers Time & numbers A look at recent drugs approved for diabetes shows about 1,400-4,000 patients in total enrolled in the major efficacy trials as part of the companies' NDA submissions. Major efficacy...
Items per page:
1 - 10 of 32